Compositions and methods related to antibodies to Staphylococcal protein A
AssigneeThe University of Chicago
InventorsOlaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
Life of this patent
Estimating the term…
Abstract
Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
Claims16
A purified chimeric polypeptide comprising an amino acid sequence comprising CDR1, CDR2 and CDR3 of both the light and heavy chains of a 5A10 monoclonal antibody (SEQ ID NO:
- 16-18, 11-13, respectively), 8E2 monoclonal antibody (SEQ ID NO:
- 26-28, 21-23, respectively), 3F6 monoclonal antibody (SEQ ID NO:
- 56-58, 51-53, respectively), 1F10 monoclonal antibody (SEQ ID NO:
- 66-68, 61-63, respectively), 3D11 monoclonal antibody (SEQ ID NO:
- 86-88, 81-83, respectively) or 2F2 monoclonal antibody (SEQ ID NO:
- 101-103, 96-98, respectively), wherein the polypeptide is capable of specifically binding at least two Spa IgG binding domains A, B, C, D and E of a Staphylococcal protein A (SpA) polypeptide variant that lacks non-specific Ig-binding activity, and wherein each of CDR1, CDR2, and CDR3 have up to one amino acid substitution.
A pharmaceutical composition comprising a purified chimeric polypeptide comprising CDR1, CDR2 and CDR3 of both the light and heavy chains of a 5A10 monoclonal antibody (SEQ ID NO:
- 16-18, 11-13, respectively), 8E2 monoclonal antibody (SEQ ID NO:
- 26-28, 21-23, respectively), 3F6 monoclonal antibody (SEQ ID NO:
- 56-58, 51-53, respectively), 1F10 monoclonal antibody (SEQ ID NO:
- 66-68, 61-63, respectively), 3D11 monoclonal antibody (SEQ ID NO:
- 86-88, 81-83, respectively) or 2F2 monoclonal antibody (SEQ ID NO:
- 101-103, 96-98, respectively), wherein the polypeptide is capable of specifically binding at least two Spa IgG binding domains A, B, C, D and E of a Staphylococcal protein A (SpA) polypeptide variant that lacks non-specific Ig-binding activity, and wherein each of CDR1, CDR2, and CDR3 have up to one amino acid substitution.
Dependencies are inferred from the claim text.